for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

IRIDEX Corporation

IRIX.OQ

Latest Trade

1.77USD

Change

-0.28(-13.66%)

Volume

34,866

Today's Range

1.72

 - 

2.03

52 Week Range

1.72

 - 

6.63

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.05
Open
2.03
Volume
34,866
3M AVG Volume
1.18
Today's High
2.03
Today's Low
1.72
52 Week High
6.63
52 Week Low
1.72
Shares Out (MIL)
13.76
Market Cap (MIL)
28.20
Forward P/E
-2.77
Dividend (Yield %)
--

Latest Developments

More

Iridex Reports Q2 2019 Results

IRIDEX QTRLY Diluted Loss Per Share $0.22

Iridex Announces 2018 Fourth Quarter And Full Year Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About IRIDEX Corporation

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company's ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

Industry

Medical Equipment & Supplies

Contact Info

1212 Terra Bella Ave

+1.650.9404700

http://www.iridex.com/

Executive Leadership

David I. Bruce

President, Chief Executive Officer, Director

Robert Earle Grove

Director

Kenneth E. Ludlum

Director

Maria Degois Sainz

Director

Scott A. Shuda

Director

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.140

2017

-1.110

2018

-1.050

2019(E)

-0.740
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.64
Price To Book (MRQ)
1.10
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-42.35
Return on Equity (TTM)
-30.96

Latest News

BRIEF-Iridex Corp Q1 Revenue $9.5 Million

* REITERATED ITS GUIDANCE FOR 2018 OF G6 PROBE SHIPMENTS OF 40,000 TO 45,000,

BRIEF-Iridex Announces Availability Of G-Probe Illuminate Device In Europe

* IRIDEX CORP - AVAILABILITY OF G-PROBE ILLUMINATE DEVICE IN EUROPE Source text for Eikon: Further company coverage:

BRIEF-Iridex Qtrly Loss Per Share $0.44

* IRIDEX ANNOUNCES 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

BRIEF-Iridex Issues Voluntary Recall Of Trufocus Lio Premiere Laser Indirect Ophthalmoscope

* IRIDEX ISSUES VOLUNTARY RECALL OF TRUFOCUS LIO PREMIERE™ LASER INDIRECT OPHTHALMOSCOPE

BRIEF-Blueline Capital Partners LP Reports 8.5 pct Passive Stake In Iridex Corp As Of Dec. 31, 2017

* BLUELINE CAPITAL PARTNERS LP REPORTS 8.5 PERCENT PASSIVE STAKE IN IRIDEX CORP AS OF DECEMBER 31, 2017 - SEC FILING Source text - (http://bit.ly/2F0uMll) Further company coverage:

BRIEF-Iridex Corp ‍Filed Lawsuit Against Quantel Medical S.A

* IRIDEX CORP - FILED LAWSUIT AGAINST QUANTEL MEDICAL S.A., QUANTEL USA, QUANTEL, S.A. IN U.S. DISTRICT COURT FOR NORTHERN DISTRICT OF CALIFORNIA Source text for Eikon: Further company coverage:

BRIEF-Iridex Corp reports qtrly loss per share $0.27

* Iridex Corp - Iridex reiterates its previously provided estimate for revenue, and g6 system and g6 probe shipments for full year 2017

BRIEF-Iridex Q2 revenue falls 16 pct

* Iridex announces 2017 second quarter, six-month financial results

BRIEF-Iridex Q1 revenue fell 12 percent to $10.5 million

* Iridex-Continues to anticipate for full year 2017 sales of 400 to 450 g6 systems, currently expects g6 probe shipments to range from 35,000 to 40,000

BRIEF-Iridex reports Q4 loss per share of $1.04

* Iridex announces fourth quarter and 2016 financial results and provides full year 2017 financial outlook

BRIEF-Iridex announces preliminary unaudited revenues for 2016 Q4 and FY

* Iridex announces preliminary unaudited revenues for 2016 fourth quarter and full year

BRIEF-Iridex reports 2016 third quarter, nine-month results

* Iridex Corp- continues to expect revenue growth for full year 2016 to be in low double-digits

BRIEF-Iridex Q3 preliminary revenues of approximately $9.6 to $9.7 mln

* Iridex announces preliminary revenues for 2016 third quarter

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up